REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,243,120 | -67.0% | 22,000 | -54.2% | 0.22% | -57.9% |
| Q2 2021 | $6,794,000 | -36.4% | 48,000 | -29.9% | 0.54% | -61.3% |
| Q2 2020 | $10,687,000 | -9.7% | 68,500 | -16.5% | 1.38% | -39.1% |
| Q1 2020 | $11,836,000 | -7.4% | 82,000 | +31.2% | 2.27% | -8.1% |
| Q4 2019 | $12,777,000 | – | 62,500 | – | 2.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $110,053,269 | 27.64% |
| Ghost Tree Capital, LLC | 500,000 | $18,995,000 | 8.11% |
| First Light Asset Management, LLC | 2,062,453 | $78,352,589 | 7.27% |
| Boxer Capital, LLC | 1,230,004 | $46,727,852 | 2.46% |
| Sofinnova Investments, Inc. | 992,029 | $37,687,182 | 2.24% |
| Tri Locum Partners LP | 141,466 | $5,374,000 | 2.17% |
| MPM BioImpact LLC | 194,181 | $7,376,936 | 1.91% |
| Ikarian Capital, LLC | 201,200 | $7,643,588 | 1.84% |
| KRS Capital Management, LLC | 28,141 | $1,069,077 | 1.46% |
| EMERALD ADVISERS, LLC | 679,772 | $25,824,538 | 1.25% |